)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Shenzhen Salubris Pharmaceuticals
Shenzhen Salubris Pharmaceuticals (002294) investor relations material
Shenzhen Salubris Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary24 Aug, 2026
Executive summary
Achieved revenue of ¥2,479,135,760.18 in H1 2026, up 16.34% year-over-year; net profit attributable to shareholders reached ¥387,091,726.75, up 6.03% year-over-year.
Innovative drug revenue grew 26.84% year-over-year, now nearly half of total revenue.
R&D investment increased 14.38% year-over-year to ¥620 million, representing 25% of revenue.
Operating cash flow improved by 9.62% year-over-year to ¥466,348,587.42.
Major pipeline progress: new drug approvals, clinical trial advancements, and device launches.
Financial highlights
Net profit excluding non-recurring items grew 15.64% year-over-year to ¥401,062,396.92.
Gross margin for innovative drugs: 83.40%; overall gross margin for pharma: 75.48%.
Basic and diluted EPS: ¥0.35, up from ¥0.33 year-over-year.
Total assets at period end: ¥11,075,120,669.16; shareholders’ equity: ¥8,566,737,291.10.
Weighted average ROE was 4.30%, up from 4.19% year-over-year.
Outlook and guidance
Continued focus on CKM (cardio-renal-metabolic) chronic disease innovation.
Multiple innovative drugs and devices expected to reach market in late 2026 and 2027.
Ongoing expansion in retail and e-commerce channels, with new business models for chronic disease management.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shenzhen Salubris Pharmaceuticals
- Revenue up 8.5%, net profit up 8.3%, innovative drug sales up 47% year-over-year.002294
Q4 2025 - Revenue and profit rose double digits year-over-year, with margin and R&D progress supporting growth.002294Q1 2026
- Q3 2025 saw 15.85% revenue growth and 30.19% net profit increase, led by new products.002294Q3 2025
- Net profit rose 6.10% on 4.32% revenue growth, led by new drugs and medical device expansion.002294Q2 2025
- Revenue and net profit rose on strong innovative product growth and robust cash flow.002294Q3 2024
- Revenue up 21.28% and net profit up 1.92% on innovation-driven growth.002294Q2 2024
- 2024 revenue rose 19.22% to ¥4.01B, net profit up 3.71%, with strong R&D and cash dividend.002294Q4 2024
- Patented and new product growth offset generic drug declines, keeping Q1 profit stable.002294Q1 2025
Next Shenzhen Salubris Pharmaceuticals earnings date
Q3 202623 Oct, 2026
Shenzhen Salubris Pharmaceuticals
Next Shenzhen Salubris Pharmaceuticals earnings date
Q3 202623 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage